New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:15 EDTHPTXHyperion Therapeutics announces RAVICTI NDS accepted by Health Canada
Hyperion Therapeutics announced that the validation period is complete for its New Drug Submission to Health Canada for RAVICTI Oral Liquid for the treatment of urea cycle disorders, and that the RAVICTI NDS was granted Priority Review. Standard review in Canada takes 18 months or more and Priority Review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review time to approximately six months. The NDS is based on results from 10 controlled and uncontrolled clinical trials studying the safety and efficacy of RAVICTI in 359 patients across three populations, including 114 UCD patients. Data from multiple Canadian patients enrolled at the University of Toronto were included in the submission. The safety and efficacy of RAVICTI is under review by Health Canada and market authorization has not yet been granted.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:38 EDTHPTXHyperion Therapeutics management to meet with Leerink
Meetings to be held in Chicago on December 2 and in New York on December 3 hosted by Leerink.
November 12, 2014
08:23 EDTHPTXHyperion Therapeutics price target lowered to $32 from $38 at Cantor
Cantor cut its price target on Hyperion after the company reported stronger than expected Q3 results but said distributors would work down 10-12 days of inventory in Q4. The company also said that it would spend $7M-$10M on terminating its DiaPep277 program, noted the firm, which keeps a Buy rating on Hyperion.
07:53 EDTHPTXLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use